MEDS DataMEDS AI, Inc.
DataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers. It offers tools, such as the EinsteinRx, a pharmacy dispensing AI platform; the PharmacyChain, a smart contracts platform; Patient Rx Adherence Tool; and HubRx AI. It also operates as a pharmacy distributor; and provides clinical concierge services. DataMEDS AI, Inc., through its subsidiary develops and delivers a portfolio of products to guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. In addition, the company develops and provides functional precision medicine oncology platform. The company was formerly known as Wellgistics Health, Inc. and changed its name to DataMEDS AI, Inc. in July 2026. DataMEDS AI, Inc. was incorporated in 2022 and is based in Tampa, Florida.…
Industry Peers
Medical DistributionKey Statistics
About DataMEDS AI (NASDAQ: MEDS)
›
DataMEDS AI (NASDAQ: MEDS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Distribution industry, part of the Healthcare sector.
The shares were at 0.7277 USD on 19 November 2026, down 97.5% over 52 weeks. Its 52-week range is 0.5048 USD to 33.15 USD: the price is 97.8% below the high and 44.2% above the low.
Its market capitalisation is 4.17M USD.
DataMEDS AI reports revenue down 77.2% year over year.
Its debt exceeds its cash by 30.17M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.